1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Savills plc
  6. News
  7. Summary
    SVS   GB00B135BJ46


Real-time Estimate Cboe Europe  -  06:17 2022-07-07 am EDT
1046.50 GBX   +1.80%
04:34aSAVILLS : Devon's farming fraternity shines at County Show
07/06SAVILLS : planning team wins at Wales Property Awards 2022
07/06SAVILLS : Leisure and Trade bolsters strength of corporate advisory with hire of Ellis Auger
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Major venture capital investment in European life sciences will fuel occupier market

11/08/2021 | 10:38am EDT

The life science sector is set to experience increased activity in the occupational and investment markets in the near future. Venture capital funding into the sector is rising at a rapid pace, and our research shows that for every €1 billion of venture capital money channelled into life sciences, 50,000 sq m of new occupier demand is generated.

There has been over €7 billion invested so far this year in Europe, exceeding the €6.9 billion placed across 2020, according to Pitchbook. At Savills we are seeing a higher allocation of venture capital targeting Germany, Switzerland, France, Belgium and the Netherlands, due to the attractive national investment environment and highly talented domestic organisations.

Venture capital investment tends to create new occupier demand between 12 and 18 months post-funding. This is generally the time a company will look for space for the next phase of their development. On that basis, the €10.2 billion of investment during 2019-20 will lead to approximately 474,000 sq m of new requirements for life sciences assets between this year and next, according to our data. As venture capital funding continues to increase year on year, we expect real estate demand to follow a similar trend.

More investment opportunities are also coming down the line. The disjointed ownership structure that characterises the European life sciences market has meant that there have been limited total transaction volumes across the continent to date. But the weight of capital seeking exposure to the sector will prompt existing legacy owners to realise the value of their properties going forward. We are also seeing an increasing number of life science-focussed development opportunities in key locations throughout the UK and Europe.

Capital markets activity is already increasing in the UK and Europe. We have seen activity in the science park segment, with GIC recapitalising a 40 per cent stake in the Oxford Science Park and CPPIB forming a partnership with Lendlease to develop MIND, a substantial innovation district in Milan on the former EXPO site.

Away from the large scale parks, there is also increasing interest in single asset opportunities in the key clusters throughout Europe. BentallGreenOak and Mission Street have acquired a retail warehouse scheme in a prominent location in Oxford for repositioning into a life science facility, and Corum has completed the acquisition of Beagle Zernike, a purpose-built life science asset in Leiden.

The fundamentals of location and cluster dynamics are so important for life science schemes to be successful, it is therefore imperative to understand the key locations throughout Europe.

Further information

Contact Mike Barnes or George Coleman

European life science: emerging hotspots


Savills plc published this content on 08 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 November 2021 15:37:07 UTC.

© Publicnow 2021
All news about SAVILLS PLC
04:34aSAVILLS : Devon's farming fraternity shines at County Show
07/06SAVILLS : planning team wins at Wales Property Awards 2022
07/06SAVILLS : Leisure and Trade bolsters strength of corporate advisory with hire of Ellis Aug..
07/06SAVILLS : signs association agreement with SUPPA in the Baltics
07/05SAVILLS : RedCat Pub Company and its subsidiary, The Coaching Inn Group, acquire Forest Pa..
07/05SAVILLS : Top tips for creating a sustainable yet chic and unique look at home
07/05SAVILLS : Prime London rental values see strongest annual growth in over 20 years
07/04SAVILLS : Growth in Prime Central London continues steady recovery, but is held back by st..
07/04IMPACTS 2022 : Inflation plus social benefits are likely to drive investment in multifamil..
07/04SAVILLS : Capital Advisors advises on majority sale of Chartway Group to Cabot Square Capi..
More news
Analyst Recommendations on SAVILLS PLC
More recommendations
Sales 2022 2 149 M 2 558 M 2 558 M
Net income 2022 115 M 137 M 137 M
Net cash 2022 48,4 M 57,6 M 57,6 M
P/E ratio 2022 13,5x
Yield 2022 3,32%
Capitalization 1 421 M 1 692 M 1 692 M
EV / Sales 2022 0,64x
EV / Sales 2023 0,59x
Nbr of Employees 39 118
Free-Float 93,0%
Duration : Period :
Savills plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAVILLS PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1 028,00 GBX
Average target price 1 309,25 GBX
Spread / Average Target 27,4%
EPS Revisions
Managers and Directors
John Jeremy Mark Ridley Group Chief Executive Officer & Director
Simon James Blouet Shaw Group Chief Financial Officer & Executive Director
Nicholas Ferguson Non-Executive Chairman
Stacey Lee Cartwright Senior Independent Non-Executive Director
Florence Tondu-Melique Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAVILLS PLC-26.99%1 692
CBRE GROUP, INC.-30.54%24 119
KE HOLDINGS INC.-20.63%20 193
ZILLOW GROUP, INC.-43.99%8 568